Shanghai MicroPort MedBot: Commercial Traction Is Real, but the Re-Rating Has Already Happened

That leaves the stock in a different place now. Fundamentally, it is much better than it was a year ago. Capital-markets-wise, the easy re-rating has already happened. Using the 2026-07-24 close and the latest reported share count, the equity is worth about HK$20.85 billion. Against 2025 revenue of about HK$638 million equivalent, that is roughly 32.7 times trailing sales; adjusting for year-end net cash, enterprise value is still about 32.2 times 2025 sales. That multiple can be defended only if 2026 and 2027 keep delivering triple-digit revenue growth, improving gross margin, and a visible shift from equipment placements toward a higher-quality installed-base revenue mix. MedBot may get there. The stock is no longer priced as though it definitely will fail. It is priced as though the hard part is now execution, and execution is beginning to work.

Company vertical history

MedBot's origin makes more sense if you see it as one piece of MicroPort's broader platform strategy. The parent has spent years creating specialized subsidiaries around therapeutic categories and technologies, giving them separate capital structures and, often, their own listed equity. MedBot fits that template: a robotics-focused arm built to absorb long gestation, high R&D intensity, and regulatory complexity that would sit awkwardly inside a more conventional device P&L. The company's own latest annual materials say 2025 marked the tenth anniversary of MedBot's inception, which points to a 2015 operating start even though some third-party databases still label the business as founded in 2014. The more reliable primary conclusion is that MedBot emerged in the mid-2010s as a robotics platform incubated inside the MicroPort ecosystem and only later asked public markets to fund industrialization.

The IPO story in 2021 was clear and, in hindsight, familiar. MedBot came to market as a high-end China medtech growth asset: multi-specialty robotic pipeline, flagship Toumai platform, parent support, and a global surgical-robotics TAM that company materials described as surging. It listed on HKEX on 2021-11-02, with an offer-price range of HK$36.00 to HK$43.20 and later disclosures showing the offering was done at HK$43.20, raising gross proceeds of about HK$1.80 billion including the over-allotment. That capital was the bridge from approval-stage promise to manufacturing, training, commercial rollout, and overseas market development.

The company's history since then splits cleanly into four stages. The first was the proof stage: product development, approvals, and public-market funding. In 2021, revenue was only RMB2.15 million, the company lost RMB582.9 million, and the market was effectively paying for a pipeline option on robotic surgery in China. The second stage was initial commercialization in 2022 and 2023. Revenue grew from RMB21.6 million in 2022 to RMB104.6 million in 2023, helped by Toumai's early placements and DFVision's first full year, but losses remained huge because commercialization costs, training, selling, and R&D were still far ahead of scale. The third stage was 2024, when commercialization broadened but the economics still looked fragile: revenue rose to RMB257.2 million, yet the company still lost RMB642.4 million and needed additional equity financing. The fourth stage began in 2025, when the shape of the business changed. Revenue more than doubled to RMB551.1 million, gross margin moved close to 50%, cash burn collapsed, and the company entered 2026 guiding to first-half profitability.

A compact view of that financial arc helps make the transition visible.

The financial pattern is the business pattern. In the first three years after listing, MedBot was paying up front for clinical adoption, physician training, market education, factory readiness, and product breadth. In 2025, those sunk costs finally met a commercial base large enough to create visible operating leverage. The sharp drop in free cash outflow matters as much as the reduction in accounting loss because it says the company's commercial model is no longer only a story told through adjusted metrics; it is beginning to show in cash.

The most important product node was Toumai's move from a China approval story to a global commercialization story. The company reported that Toumai received EU CE MDR certification in May 2024, making it the first domestic laparoscopic surgical robot with EU CE marking. By the first half of 2025, Toumai had over 80 cumulative commercial orders and more than 60 cumulative commercial installations worldwide. By the company's 2025 year-end profit guidance announcement in January 2026, Toumai had accumulated more than 180 commercial orders and over 120 commercial installations worldwide. Those figures settle the inconsistency in older headlines. The "70+ orders / 50+ installs" and "130 global orders" numbers were snapshots taken at different dates; the newest precise primary disclosure is the January 2026 figure.

SkyWalker is the second key node because it broadened MedBot from soft-tissue robotics into the orthopedic robot market where Stryker's Mako is the reference standard. In the 2025 interim report, SkyWalker had cumulative global orders above 55 and cumulative installations above 35, with clinical applications in hospitals across China, Europe, and North America. By the 2025 annual results announcement, cumulative global orders had moved above 65, and the company said SkyWalker had obtained listing approvals in nearly twenty countries and regions, including China's NMPA, the U.S. FDA, and EU CE. Health Canada approval arrived in January 2025, which the company highlighted as another meaningful addition to developed-market access. The business point is simple: SkyWalker is not yet remotely close to Mako's scale, but it is no longer a purely domestic orthopedic widget. It is a real international orthopedic robot franchise, albeit an early one.

The product portfolio is now broad enough that MedBot's "five-specialty" claim deserves to be taken seriously. The 2025 annual results announcement said the company was the only surgical-robotics company in the world with a portfolio spanning laparoscopic, orthopedic, panvascular, natural orifice, and percutaneous procedures, and that by year-end it had become the first and only company to realize approval and commercialization of full-spectrum products across those specialties. Toumai Single-port obtained NMPA approval in February 2025, Toumai Remote became the world's first remote surgical robot approved for commercial use in April 2025, R-ONE accelerated after its December 2023 NMPA approval, Mona Lisa had already been commercialized after its 2023 NMPA approval, and UniPath obtained NMPA approval in December 2025 and entered commercialization. That breadth is strategically valuable, but it does not mean each product contributes equally to revenue today. The filings still point back to Toumai and SkyWalker as the real commercial engines.

The capital-markets nodes that still matter today are the 2024 and 2025 placings. In July 2024 the company completed a placing of 12.9 million H shares at HK$9.10. In May 2025 it placed another 25.14 million new H shares at HK$15.50, raising gross proceeds of approximately HK$390 million. The equity dilution is real, and it is one reason investors should not romanticize "growth." But the placings also bought time precisely when the company was turning revenue growth into margin improvement. In other words, they were dilution used to cross an operating inflection, not dilution to keep a broken model alive for one more year.

Business model, industry, and competition

MedBot's business model today is still dominated by capital equipment placement, but its long-run economics depend on becoming something else. The mature robotics model is not "sell a very expensive robot once." It is "place a robot, entrench a surgeon, standardize workflow, then monetize instruments, accessories, service, maintenance, upgrades, and training over many years." Intuitive is the benchmark for that model. In 2025, Intuitive generated about $10.1 billion of revenue, including about $6.02 billion from instruments and accessories, while ending the year with an installed base above 12,100 systems and more than 3.1 million procedures. That is what a fully formed robotics annuity looks like. MedBot is not there yet. It is still much closer to the placement phase than the recurring phase.

That gap explains both the opportunity and the risk. The opportunity is obvious: once a robot is installed, surgeon habits, training pathways, hospital workflow, compatible instruments, and service contracts can create stickiness. The risk is that before that installed base reaches escape velocity, the economics remain lumpy. Orders can outrun recognized revenue. Revenue can outrun cash collection. And channel assistance can flatter scale before direct end-user demand is fully proven. MedBot's 2025 receivables jump is consistent with a business expanding fast through distribution and hospital sales cycles: trade receivables rose to RMB208.8 million at year-end 2025 from RMB33.1 million a year earlier, even as cash improved thanks to equity financing and tighter free cash outflow. That does not prove any problem, but it does say the company is still in the messy part of commercialization, not the serene annuity phase.

The moat is therefore narrower than the marketing sometimes implies, but it is not imaginary. The first real moat is regulatory and clinical breadth. MedBot now has approved products across multiple specialties, and that breadth is rare. The second is parent-enabled distribution. The parent acts as a commercial accelerant, not just a shareholder, lending orthopedic and overseas channels that MedBot would have taken far longer to build by itself. The third is remote-surgery know-how. Toumai Remote obtained the world's first registration certificate for a remote surgical robot in China, and the company says Toumai has completed nearly 800 remote surgeries worldwide by the 2025 annual report date. Those are meaningful differentiators. What MedBot does not yet have is the strongest moat in surgical robotics: a massive high-frequency procedure ecosystem of the kind Intuitive built over two decades.

The governance picture is functional but carries a clear structural discount. KPMG remained the auditor in the latest annual and interim filings, and I did not find any disclosed accounting scandal or auditor rupture in the materials reviewed. The more important governance issue is dependence on the parent. MicroPort remains the controlling shareholder, and the parent's own 2025 annual report said its equity interest in MedBot had diluted to 43.98%, with voting rights of 45.63% because of an acting-in-concert agreement. At the operating level, related-party arrangements cover product sales/distribution, property management, catering, and other support services. This structure lowers commercialization friction, but it also means shareholders are buying a partially independent public company whose fastest growth channel still runs through the parent group. That is worth a valuation discount, not because the arrangement is necessarily abusive, but because it reduces analytical clarity.

The industry backdrop is better than the 2022-2024 stock chart once suggested. MedBot's own market materials, drawing on external industry data, described the global surgical-robot market as rising from $7.7 billion in 2019 to $21.2 billion in 2024 and projecting $84.2 billion by 2033. Older company materials and related contemporaneous reporting also cited a China surgical-robotics market expected to reach about $3.8 billion in 2026, with China's share of the global market rising from about 5% in 2020 to 11% in 2026. Those numbers are useful context, but the real operating lesson is not "the TAM is huge." It is that China still has room for penetration growth while global incumbents are crowding the field faster than before.

The horizontal portrait of peers shows why MedBot can win business without yet looking financially comparable to the incumbents.

The business reason behind these differences matters more than the table. Intuitive sells a procedure ecosystem. Hospitals buy da Vinci, but the real economic engine is the steady stream of instruments, accessories, and service revenue attached to a giant installed base. Stryker does something similar in orthopedics, though embedded in a broader implant-and-capital-equipment complex rather than a pure-play robotics model. Medtronic's advantage is not that Hugo is already dominant. It is that Medtronic can fund a long global rollout, bundle adjacent surgical tools, and tolerate slow payback. MedBot's edge is different again. It competes by being the most credible China-origin multi-specialty surgical-robotics challenger already in commercial scale-up, with a parent willing to lend channels and a price/value proposition that can work in markets where da Vinci economics remain hard to justify. What it lacks is peer-level installed-base density and peer-level recurring revenue visibility.

The competitive set is also widening, not narrowing. Medtronic says Hugo is now available in more than 35 countries and has U.S. clearance in urology, with submissions pending for general surgery and gynecology. CMR said in March 2026 that more than 45,000 patients had been treated using Versius, and its U.S. clearance opens another phase of competition. On 2026-07-22, Johnson & Johnson's Ottava received FDA marketing authorization in the U.S., officially adding another large-capitalized entrant to soft-tissue robotics. That matters for MedBot even outside the United States, because global robotics is becoming a multi-platform market with credible alternatives, not a da Vinci monopoly plus copycats. MedBot's product cadence has improved fast enough to matter, but its future gross margin will still be set in a battlefield that keeps getting more crowded.

Current fundamentals

Because MedBot reports on a semiannual rhythm rather than quarterly, the cleanest way to read "the last four quarters" is to stack the latest annual report, the 2025 interim report, and the July 2026 profit alert. On that basis, the operating direction is unusually clear. First half 2025 revenue grew 77% to RMB175.7 million, with the company saying Toumai achieved 22 commercial installations during the period and R-ONE achieved commercial sales and installation of five units. Full-year 2025 revenue then accelerated to RMB551.1 million, with gross margin reaching 48.4% and free cash outflow falling to RMB63 million. Then, on 2026-07-23, the company guided to first-half 2026 net profit of RMB28 million to RMB40 million and revenue growth of roughly 200% to 230%. The apparent sequence is not "a one-off profit alert." It is 18 months of steadily improving commercial conversion.

The strongest current operating fact is overseas traction. In 2025, overseas revenue rose 189.4% to RMB400.2 million, making overseas markets 72.6% of total revenue. Toumai had obtained certifications in more than 60 countries and regions by the 2025 annual results announcement, while Toumai Remote had approvals in nearly ten countries and SkyWalker had approvals in nearly twenty countries and regions including NMPA, FDA, and CE. The company's growth is no longer dependent on a single China tender cycle, and MedBot is leaning into a strategy that looks much more like export-led scaling than many investors originally assumed.

The second current fundamental is cost discipline. Management has been talking about "cost reduction and efficiency improvement" since 2023, but in 2025 and 2026 the numbers finally match the phrase. The 2025 annual results announcement said net free cash outflow fell 84% year on year, and the 2025 interim report had already shown first-half free cash outflow down 42.8% year on year to RMB134.6 million. In July 2026 the company explicitly attributed the expected swing to first-half profitability to both strong revenue growth and significantly lower operating expenses. In plain terms, MedBot appears to have done the difficult thing: it did not wait for perfect scale before trying to simplify the cost base.

The market is trading three live ideas right now. The first is the profit-inflection trade. The second is overseas expansion, especially for Toumai. The third is the "China robotics platform" story, strengthened by the company's sequence of remote-surgery milestones and regulatory wins. There is a real fundamental base under all three. But the narrative can still run ahead of the economics because MedBot has not yet disclosed the kind of recurring revenue mix that would prove its installed base is monetizing like a mature platform. Investors are therefore paying for direction, not yet for a stabilized model.

A short investor dashboard is enough to show what matters next.

The reason these indicators matter is straightforward. Orders tell you whether the funnel is alive. Installations tell you whether the funnel is converting. Gross margin tells you whether pricing and manufacturing are improving rather than merely volume rising. Free cash flow tells you whether the model is financed by customers or by shareholders. Receivables tell you whether booked revenue is translating into collected cash. And the next formal interim report, likely around late August 2026 by comparison with the 2025 interim reporting schedule, is the event where bulls will look for proof that the July profit alert did not simply pull forward expectations.

Valuation analysis

MedBot's valuation history is the history of a market learning how not to price pre-profit robotics. The stock came public at HK$43.20, rallied early, later collapsed to HK$6.04 in September 2024, and by 2026-07-24 had recovered to HK$20.22. That path reflects more than sentiment. It reflects at least three valuation centers. At listing, the market used a category multiple: surgical robotics was scarce, exciting, and easy to compare to Intuitive at a story level. By 2023 and much of 2024, the market used a commercialization-discount multiple: rapid revenue percentage growth counted for less when the absolute base was still tiny and losses were large. By 2025-2026, the stock moved into a profit-inflection multiple: still expensive on trailing revenue, but no longer priced as though recurring dilution was inevitable.

The first valuation discipline here is cash-flow passthrough. MedBot is still loss-making in its latest full year, so P/E is not the right anchor. Owner-earnings analysis also tells you not to treat reported revenue growth as self-validating. The company itself defines free cash flow conservatively as operating cash flow less purchases of property, plant and equipment and intangible assets, plus lease-related cash uses. On that basis, free cash outflow improved from RMB388 million in 2024 to RMB63 million in 2025, and second-half 2025 free cash flow turned positive. That means accounting loss and cash loss have unusually rapidly converged in the right direction. It is one of the strongest facts in the case.

At the current share price, the company is still expensive on trailing revenue. Using the 2026-07-24 close and the latest reported share count, MedBot's market value is about HK$20.85 billion. Using year-end 2025 cash of RMB636.3 million and debt of RMB389.1 million, net cash was only modestly positive in HKD terms, so enterprise value and market value are close. Against FY25 revenue of RMB551.1 million, or around HK$638 million, the stock trades at roughly 32.2 times trailing EV/sales. That is far above broad medtech norms and also above Intuitive's simple trailing price-to-sales ratio of roughly 11.9 times based on a $120.6 billion market cap and 2025 revenue of about $10.1 billion. Stryker and Medtronic sit much lower on simple sales multiples because they are mature diversified device franchises. The market is therefore awarding MedBot a very large premium for duration and future mix shift, not for current cash generation.

That does not automatically make the stock wrong. It means absolute valuation has to be built around an early-commercial medtech framework, not around trailing earnings. I therefore use scenario EV/sales anchored to whether MedBot can turn 2025's placement wave into a broader installed-base model.

This is valuation-scenario analysis within a research framework, not investment advice. The critical conclusion is that the current price already sits close to the base case. The market is not pricing MedBot as though it were still a distressed cash-burn story. It is pricing a good part of the operating turn already.

The expectation gap therefore lies in quality of revenue, not merely quantity of revenue. Bulls will focus on top-line acceleration and first profit. Bears will focus on whether profitability comes with rising receivables, parent-channel concentration, and a still-light consumables/service disclosure. If the next formal result confirms first-half profitability and shows another step down in cash burn, the stock can hold a premium. If gross margin softens or trade receivables keep expanding faster than sales, the premium multiple can compress very quickly because the market will conclude MedBot is still a placer of boxes, not yet a builder of annuities.

Margin of safety is the uncomfortable part of the story. At HK$20.22, the share price is well above the value implied by the conservative scenario of roughly HK$12.4. That means the current price offers no margin of safety against execution slips. If the base case assumptions are cut to 70% of their intended commercial force, a reasonable derivative value lands back near the low-teens, not far from the conservative case. And if MedBot merely flat-lines rather than compounds over the next three years, the most likely outcome is multiple compression, not acceptable carrying return. This is the classic "good company transition, demanding price discipline" setup.

Cross-synthesis summary

Vertically, the capability MedBot has genuinely proven is not full moat maturity. It is something earlier and still important: the ability to take a complex, capital-intensive, China-origin surgical-robot platform out of the approval stage and into real hospital installations across multiple specialties and geographies. That is a nontrivial achievement. Many medtech companies can build a pipeline deck. Far fewer can get from "NMPA approval" to "meaningful overseas revenue," and fewer still can do it while improving gross margin and sharply shrinking cash burn. MedBot has now done that much. The past success came from several forces working together: a real technology base, disciplined product breadth, the MicroPort group's channel help, and a market window in which hospitals around the world became more willing to evaluate non-incumbent robotic systems. Those factors are still present, but they are no longer enough by themselves. The next phase needs a better revenue mix, cleaner cash conversion, and proof that the parent-assisted route to market can eventually stand more on its own feet.

Horizontally, MedBot's real advantage is not that it already matches Intuitive, Medtronic, or Stryker on economics. It does not. The advantage is that it is the most credible listed Chinese challenger with commercial products already spanning laparoscopic, orthopedic, vascular, natural-orifice, and percutaneous robotics, and with enough regulatory progress overseas to move the story beyond domestic substitution alone. Its weakness is structural only if it never develops a higher-quality installed-base revenue model. Right now that part is still unresolved. The current valuation is therefore rewarding future success more than past success. Past success justifies survival and relevance. The current multiple asks for repeatable scaling. The market's likely misjudgment is that profit inflection and platform maturity are the same thing. They are not. Profit inflection can arrive earlier than platform maturity, especially when parent channels accelerate rollout.

Over the next year, the decisive variables are gross margin, receivables, and conversion of the July 2026 profit alert into a clean formal interim report. Over three years, what matters is whether Toumai and SkyWalker create a recurring instruments/service base large enough to make MedBot analytically resemble a medtech platform rather than a lumpy capital-equipment exporter. Over five years, the open question is whether MedBot can become one of the few truly global non-Western surgical-robotics companies, or whether it remains a strong regional challenger with selective export success. It becomes a better investment if three things happen together: recurring revenue disclosure improves, related-party channel reliance falls as a share of sales, and profitability persists without repeated equity dilution. The original judgment should be revisited if gross margin falls below 40% for two consecutive reporting periods, if receivables continue to outrun revenue growth, if Toumai's order-to-installation conversion stalls, or if the parent-channel share of sales remains stubbornly dominant even as scale rises.

The bull case is strong enough to respect. Toumai already had more than 180 orders and more than 120 commercial installations by January 2026, which is real proof of demand. SkyWalker has meaningful overseas approvals, including FDA, CE, and Health Canada, giving MedBot a second commercial pillar outside laparoscopy. 2025 gross margin and free cash flow improved much faster than many early-commercial medtech names manage. And the July 2026 profit alert suggests the move from "cash consumer" to "operating business" may be arriving earlier than the market feared.

The bear case is just as real. First, the company still does not disclose a peer-grade recurring revenue split, so investors are asked to infer quality from placements and narrative. Second, related-party sales with the MicroPort group were about RMB391.6 million in 2025, or roughly 71% of company revenue, which makes channel independence an unresolved issue. Third, the stock already discounts substantial future success at roughly 32 times trailing EV/sales. Fourth, receivables expanded sharply with revenue in 2025, which means commercialization quality still needs monitoring. Fifth, the competitive field is getting harder, not easier, with Medtronic, CMR, and now J&J all pushing forward in robotics.

A realistic pre-mortem has two plausible scripts. In the first, 2026 proves to be the peak year for order growth rather than the start of a stable annuity. Parent-channel sales front-load overseas placements, but end-user utilization and consumables pull do not keep pace. By 2027, revenue growth slows to the 20% range, gross margin slips back toward the low-40s, receivables stay stretched, and the market cuts the valuation from roughly 32 times trailing sales today toward 12 to 15 times forward sales. In that script, the stock can fall into the low-teens or worse. In the second script, competition intensifies faster than MedBot can build stickiness. Hugo expands, CMR gains U.S. credibility, and price pressure rises in export markets. MedBot responds by discounting systems to protect installations, but because the recurring revenue base is still immature, the margin hit lands immediately while payback is delayed. The multiple then compresses at the same time the profit story wobbles. A 50% drawdown is not remotely impossible in that scenario.

At the current price, I think MedBot is worth owning only with disciplined expectations. It is one of the more interesting public surgical-robotics challengers because it now has enough commercial evidence to matter, and because the latest disclosures show a genuine operating turn rather than just a TAM story. But the stock is no longer early enough to forgive any evidence gap. The core attraction is straightforward: MedBot has moved from proof-of-concept to scaled commercialization faster than many expected, and the first-half 2026 profit alert says the business may be exiting the worst part of the cash-burn era. The core worry is just as straightforward: the market has already paid up for that transition, while the company still has not fully proven independent channel quality or a mature recurring-revenue engine.

I would change my mind to a more constructive stance if the next two formal reporting periods confirm three things at once: sustained profitability, receivables discipline, and clearer disclosure that the installed base is generating higher-quality recurring revenue rather than just more placements. I would turn materially more cautious if first-half 2026 profit proves one-off, if gross margin gives back the 2025 gains, or if connected-party sales remain the dominant route to revenue even as scale grows. MedBot has earned a place on serious investors' watch lists. It has not yet earned blind trust at any price.

【Company-profile scores】

• Fundamental quality: medium
• Growth: high
• Moat: medium
• Financial soundness: medium
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: high
• Suitable investor type: high-risk speculation

【Investment rating】

• Rating: Hold
• One-line thesis: Commercial traction and profit inflection are real, but the stock already prices much of the transition while channel dependence and revenue-quality questions remain.
• 【Ideal Buy Price】8–10 HKD Basis: at least a 20% margin of safety below the conservative scenario value of about HK$12.4 per share.
• Acceptable hold price: 18–25 HKD
• Clearly overvalued price: above 39 HKD
• Current-price classification: acceptable hold.
• Whether to wait for a better price: yes. A more attractive entry would need either a pullback toward the low-teens or another 1–2 reporting periods proving that recurring economics are catching up with the valuation. The opportunity cost of waiting is missing a further re-rating if first-half profitability becomes full-year profitability quickly.
• Target holding horizon: 3–5 years.
• Expected annualized return: conservative about -15%; base about 2%; optimistic about 20%, using the scenario values as a three-year outcome frame.
• Max-loss risk: about 50% if commercialization quality disappoints, gross margin fades, and the multiple compresses toward a low-teens share-price range.
• Reassessment-trigger signals: gross margin below 40% for two consecutive reporting periods; receivables growing faster than revenue again; Toumai installation growth materially lagging order growth; another major equity raise before a stable profit profile is established; related-party channel sales remaining dominant without clearer independent demand evidence.

【Valuation Range】

• current: 20.22 (close as of 2026-07-24)
• bear (conservative · ideal buy zone): [8, 10]
• base (fair · acceptable hold zone): [18, 25]
• bull (optimistic · above the clearly-overvalued line): [39, 45]

Research uncertainties: first, MedBot still does not disclose product-level revenue, so Toumai's exact contribution remains inferred rather than reported; second, current parent-ownership detail is clearer in MicroPort's 2025 annual report than in the snippets available from MedBot's own annual report; third, the next formal 2026 interim reporting date has not yet been pinned down by a company calendar notice in the materials reviewed, so late August 2026 is an inference from prior practice; fourth, peer valuation comparisons for Medtronic and Stryker are imperfect because robotics is only one part of much larger medical-device groups; fifth, the latest precise Toumai order/install-base disclosure available in primary materials appears to be January 2026, so any internal company presentations after that date could show higher counts not yet captured in formal filings.

Source basis: I relied primarily on MedBot's 2025 annual results announcement, 2025 interim report, the July 2026 preliminary earnings guidance announcement, HKEX/IR listing documents and placements announcements, parent MicroPort's 2025 annual report for ownership context, and official or primary company disclosures from Intuitive, Medtronic, Stryker, CMR Surgical, and J&J for peer positioning.

Other tickers mentioned

• ISRG.US: closest global pure-play peer and the benchmark for installed-base recurring economics in soft-tissue robotic surgery.
• MDT.US: large-cap challenger in soft-tissue robotics through the Hugo platform, useful for scale and capital-markets comparison.
• SYK.US: best orthopedic robotics benchmark through Mako, directly relevant to SkyWalker.
• 00853.HK: MedBot’s parent and controlling shareholder, important for ownership, related-party sales, and channel support.
• JNJ.US: new soft-tissue robotics entrant after Ottava’s July 2026 FDA authorization, relevant for future competitive intensity.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.